CheckMate 459: A randomized, multi-center phase III study of nivolumab (NIVO) vs sorafenib (SOR) as first-line (1L) treatment in patients (pts) with...

Keywords

MedicineSorafenibNivolumabHepatocellular carcinomaInternal medicineOncologyFirst lineGastroenterologyCancerImmunotherapy

Affiliated Institutions

Related Publications

Progression after the next line of therapy (PFS2) and updated OS among patients (pts) with advanced NSCLC and PD-L1 tumor proportion score (TPS) ≥50% enrolled in KEYNOTE-024.

Katsuyuki Hotta , Melanie A. Leiby , Jessica McLean +15 more

9000 Background: In KEYNOTE-024 (NCT02142738), pembrolizumab (pembro) was superior to chemotherapy (chemo) as first-line (1L) therapy for advanced NSCLC with PD-L1 TPS ≥50% and ...

2017 Journal of Clinical Oncology 53 citations

Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial

Andrew X. Zhu , Yoon‐Koo Kang , Chia‐Jui Yen +21 more

Patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations have poor prognosis. We aimed to establish the efficacy of ramucirumab in patien...

2019 The Lancet Oncology 1593 citations

Efficacy and Safety of Nivolumab Plus Ipilimumab in Patients With Advanced Hepatocellular Carcinoma Previously Treated With Sorafenib

Thomas Yau , Yoon‐Koo Kang , Tae‐You Kim +18 more

ClinicalTrials.gov Identifier: NCT01658878.

2020 JAMA Oncology 1129 citations

Safety and antitumor activity of biweekly MDX-1106 (Anti-PD-1, BMS-936558/ONO-4538) in patients with advanced refractory malignancies.

Mario Sznol , John D. Powderly , David C. Smith +7 more

2506 Background: Programmed death-1 (PD-1), a T-cell inhibitory receptor, may suppress antitumor immunity. MDX-1106, a fully human IgG4 PD-1 blocking antibody, has shown antitum...

2010 Journal of Clinical Oncology 84 citations

Immunotherapies for hepatocellular carcinoma

Josep M. Llovet , Florian Castet , Mathias Heikenwälder +6 more

Liver cancer, more specifically hepatocellular carcinoma (HCC), is the second leading cause of cancer-related death and its incidence is increasing globally. Around 50% of patie...

2021 Nature Reviews Clinical Oncology 1590 citations

Publication Info

Year: 2019
Type: article
Volume: 30
Pages: v874-v875
Citations: 634
Access: Closed

External Links

View on DOI.org

Social Impact

Altmetric

CheckMate 459: A randomized, multi-center phase III study of nivolumab (NIVO) vs sorafenib (SOR) as first-line (1L) treatment in patients (pts) with advanced hepatocellular carcinoma (aHCC)

PlumX Metrics

Social media, news, blog, policy document mentions

Citation Metrics

634

OpenAlex

Cite This

APA Style

                            
                                    Thomas Yau, 
                                
                                    J.W. Park, 
                                
                                    Richard S. Finn
                                
                                et al.
                            
                            (2019). 
                            CheckMate 459: A randomized, multi-center phase III study of nivolumab (NIVO) vs sorafenib (SOR) as first-line (1L) treatment in patients (pts) with advanced hepatocellular carcinoma (aHCC). 
                            Annals of Oncology
                            , 30
                            
                            , v874-v875.
                            https://doi.org/10.1093/annonc/mdz394.029

Identifiers

DOI: 10.1093/annonc/mdz394.029